Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?

Franceschi E, Tosoni A, De Biase D, Lamberti G, Danieli D, Pizzolitto S, Zunarelli E, Visani M, Di Oto E, Mura A, Minichillo S, Scafati C, Asioli S, Paccapelo A, Bartolini S, Brandes AA.

Oncologist. 2019 Feb 18. pii: theoncologist.2018-0549. doi: 10.1634/theoncologist.2018-0549. [Epub ahead of print]

PMID:
30777895
2.

Deferred radiotherapy and upfront procarbazine-ACNU-vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade.

Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Suzuki SO, Iwaki T, Shono T, Mizoguchi M, Iihara K.

Onco Targets Ther. 2016 Nov 17;9:7123-7131. eCollection 2016.

3.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.

Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27.

4.

Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.

Figarella-Branger D, Bouvier C, de Paula AM, Mokhtari K, Colin C, Loundou A, Chinot O, Metellus P.

J Neurooncol. 2012 Nov;110(2):205-13. doi: 10.1007/s11060-012-0953-x. Epub 2012 Aug 14.

PMID:
22890969
5.

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C.

Oncotarget. 2015 Oct 6;6(30):30295-305. doi: 10.18632/oncotarget.4497.

6.

Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.

McNamara MG, Jiang H, Lim-Fat MJ, Sahebjam S, Kiehl TR, Karamchandani J, Coire C, Chung C, Millar BA, Laperriere N, Mason WP.

Can J Neurol Sci. 2017 May;44(3):288-294. doi: 10.1017/cjn.2016.420.

PMID:
28488951
7.

Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.

Yamamichi A, Ohka F, Aoki K, Suzuki H, Kato A, Hirano M, Motomura K, Tanahashi K, Chalise L, Maeda S, Wakabayashi T, Kato Y, Natsume A.

Brain Tumor Pathol. 2018 Apr;35(2):106-113. doi: 10.1007/s10014-018-0312-5. Epub 2018 Mar 17.

PMID:
29550880
8.

Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.

Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM.

J Neurooncol. 2017 Aug;134(1):177-188. doi: 10.1007/s11060-017-2506-9. Epub 2017 May 25.

9.

Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.

Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H.

Neurosurg Focus. 2015 Mar;38(3):E2. doi: 10.3171/2015.1.FOCUS14745. Review.

PMID:
25727224
10.

Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis.

Zhang ZY, Chan AK, Ng HK, Ding XJ, Li YX, Shi ZF, Zhu W, Zhong P, Wang Y, Mao Y, Yao Y, Zhou LF.

Int J Clin Exp Pathol. 2014 Dec 1;7(12):8627-36. eCollection 2014.

11.

Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.

Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D.

J Neurooncol. 2015 Sep;124(2):197-205. doi: 10.1007/s11060-015-1822-1. Epub 2015 Jun 2.

PMID:
26033545
12.

Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas.

Ducray F, Mokhtari K, Crinière E, Idbaih A, Marie Y, Dehais C, Paris S, Carpentier C, Dieme MJ, Adam C, Hoang-Xuan K, Duyckaerts C, Delattre JY, Sanson M.

Eur J Cancer. 2011 Mar;47(5):802-8. doi: 10.1016/j.ejca.2010.11.031. Epub 2010 Dec 29.

PMID:
21194923
13.

Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.

Figarella-Branger D, Maues de Paula A, Colin C, Bouvier C.

Rev Neurol (Paris). 2011 Oct;167(10):683-90. doi: 10.1016/j.neurol.2011.07.006. Epub 2011 Sep 1. Review.

PMID:
21889777
14.

Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.

Karsy M, Guan J, Huang LE.

J Neurosurg. 2018 Mar 16;130(1):56-66. doi: 10.3171/2017.9.JNS172036.

PMID:
29547090
15.

Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.

Lecavalier-Barsoum M, Quon H, Abdulkarim B.

Cochrane Database Syst Rev. 2014 May 15;(5):CD007104. doi: 10.1002/14651858.CD007104.pub2. Review.

PMID:
24833028
16.

Huge heterogeneity in survival in a subset of adult patients with resected, wild-type isocitrate dehydrogenase status, WHO grade II astrocytomas.

Poulen G, Gozé C, Rigau V, Duffau H.

J Neurosurg. 2018 Apr 20:1-10. doi: 10.3171/2017.10.JNS171825. [Epub ahead of print]

PMID:
29676695
17.

IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.

Darlix A, Deverdun J, Menjot de Champfleur N, Castan F, Zouaoui S, Rigau V, Fabbro M, Yordanova Y, Le Bars E, Bauchet L, Gozé C, Duffau H.

J Neurooncol. 2017 May;133(1):37-45. doi: 10.1007/s11060-017-2421-0. Epub 2017 Apr 22.

PMID:
28434111
18.

Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma.

Suchorska B, Giese A, Biczok A, Unterrainer M, Weller M, Drexler M, Bartenstein P, Schüller U, Tonn JC, Albert NL.

Neuro Oncol. 2018 Jan 22;20(2):279-288. doi: 10.1093/neuonc/nox153.

19.

Current management of low-grade gliomas.

Hottinger AF, Hegi ME, Baumert BG.

Curr Opin Neurol. 2016 Dec;29(6):782-788. Review.

PMID:
27676279
20.

Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma.

Liu Z, Zhang T, Jiang H, Xu W, Zhang J.

Acad Radiol. 2018 Nov 1. pii: S1076-6332(18)30461-6. doi: 10.1016/j.acra.2018.09.022. [Epub ahead of print]

PMID:
30393056

Supplemental Content

Support Center